α & β -Synuclein – Recombinant Proteins


AnaSpec is pleased to announce the release of two new recombinant proteins, α -synuclein(SNCA) and β -Synuclein (SNCB). These proteins, along with g-synuclein (SNCG), are members of the synuclein family of small proteins expressed primarily in neural tissue and in some tumors.1 Synuclein proteins, found only in vertebrates, possess a highly conserved N-terminal domain, with a variable number of 11-residue repeats and a less conserved C-terminal, with a preponderance of acidic residues.1

α-Synuclein
α-Synuclein is an abundant protein of 140 residues that is present in high concentration at presynaptic terminals and is found in both soluble and membrane-associated fractions of the brain. Several possible functions have been suggested, among which are vesicle release and trafficking. In vitro incubation in the presence of salt (i.e. 0.1M NaCl) with agitation causes α-Synuclein to form fibrils.2-6 α -Synuclein, labeled with AnaSpec’s proprietary green dye, HiLyte™ Fluor 488 (Ex/Em=503/525 nm) is also available.
Figure. 1 SDS-PAGE of recombinant a-synuclein showed a single band at ~17 kDa. Figure 2. Western blot of recombinant a-synuclein protein, cat# 55456 probed with anti-a-synuclein (CT), cat # 53878. An immunoreactive band was detected at ~17 kDa (A); the band was blocked by the immunizing peptide (B). HiLyte™ Fluor 750 conjugated secondary antibody was used and signals were detected using a near infrared-fluorescence scanner (Odyssey, Li-Cor). Right panel is the grayscale image of the western blot.


Figure 3. Mass spectrometry of recombinant human asynuclein showed a single peak with the mass of 14460 Da.

Figure 4. Left: SDS-PAGE of HiLyte™ Fluor 488-labeled human a-synuclein, cat# 55457 showed a single band at ~17 kDa position. α-synuclein, non-labeled (A), HiLyte™ Fluor 488-labeled (B). Right: Fluorescence spectrum of HiLyte™ Fluor 488-labeled human α-synuclein.
Product

Size

Catalog #

Recombinant human α - synuclein (1 - 140) NEW

500 µg

55456

Recombinant human α - synuclein (1 - 140), HiLyte™ Fluor 488 labeled NEW

200 µg

55457


The addition of a-synuclein protein further complements AnaSpec’s extensive portfolio of Alzheimer’s research products.

β-Synuclein
N-terminal of β-synuclein is highly homologous to α-, γ-synucleins and consists of degenerative “KTKEGV” repeats.7-10 Similar to α-synuclein, beta-synuclein is found primarily in the brain; however, it does not associate with Lewy bodies in Parkinson disease like α-synuclein.7-10 Beta-synuclein was found to inhibit production of phosphatidic acid by the phospholipase D2 transmembrane protein in vitro.7 In addition, β-synuclein was detected in many breast and ovarian tumors.7 Recent investigations demonstrated that β-synuclein can induce mild experimental autoimmune encephalomyelitis (EAE) in Lewis rats.8

Figure 5. Figure. 1 SDS-PAGE of recombinant human b-synuclein showed a single band at ~18 kDa (slightly different than the predicted mass), CL=crude lysate; P=purified b-synuclein.

Figure 6. Western blot of recombinant b-synuclein protein, cat# 55458 probed with anti-b-synuclein (CT), cat # 53879. HiLyte™ Fluor 750 conjugated secondary antibody was used and signals were detected using a near infrared-fluorescence scanner (Odyssey, Li-Cor).


Product

Size

Catalog #

Recombinant Human β - Synuclein (1 - 134) NEW

0.5 mg

55458-500

Recombinant Human β - Synuclein (1 - 134) NEW

1 mg

55458-1000

Click here to request additional information

Related Products
Human β - Secretase (BACE1) enzyme
NEW

World’s largest collection of b-Amyloid Peptides

References
1. George, JM. Genome Biol. 3, reviews 3002.1 (2002).
2. Trojanowski, JQ. & VM. Lee, Ann. N. Y. Acad. Sci. 991, 107 (2003).
3. Masliah, E., et al. Science 287, 1265 (2000).
4. Van Der, P. H, et al. J. Neurosci. 20, 6021 (2000).
5. Feany, MB. & WW. Bender, Nature 404, 394(2000).
6. Weinreb, P. H., et al. Biochemistry 35, 13709 (1996).
7. Rivers, R.C. et al. Protein Sci 17, 887 (2008).
8. Sung, Y-H. et al. Protein Sci 15, 1162 (2006).
9. George, JM. Genome Biol 3, 3002.1 (2001).
10. Bruening, W. et al. Am Cancer Soc 88, 2154 (2000).
11. Kela-Madar, N. et al. J Neuroimmunol 208, 19 (2009).